OverviewThere are 3 main histologic types of thyroid carcinoma: differentiated (including papillary, follicular, and Hürthle), medullary, and anaplastic (aggressive undifferentiated tumor). Of 53,856 patients treated for thyroid carcinoma between 1985 and 1995, 80% had papillary, 11% had follicular, 3% had Hürthle cell, 4% had medullary, and 2% had anaplastic thyroid carcinoma.1 These NCCN guidelines focus on medullary thyroid carcinoma (MTC). Another NCCN guideline addresses papillary, follicular, Hürthle cell, and anaplastic thyroid carcinomas (see NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma [to view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org]).MTC derives from the neuroendocrine parafollicular calcitonin-producing (C) cells of the thyroid.2–4 Sporadic MTC accounts for approximately 80% of all cases of the disease. The remaining cases consist of inherited tumor syndromes, such as multiple endocrine neoplasia type 2A (MEN 2A), which is the most common type; MEN 2B; or familial MTC.5,6 Sporadic disease typically presents in the fifth or sixth decade. Familial forms of the disease tend to present at earlier ages.2Because the C cells are predominantly located in the upper portion of each thyroid lobe, patients with sporadic disease typically present with upper pole thyroid nodules. Metastatic cervical adenopathy appears in approximately 50% of patients at initial presentation. Symptoms of upper aerodigestive tract compression or invasion are reported by up to 15% of patients with sporadic disease.7Symptoms from distant metastases in the lungs or bones occur in 5% to 10% of patients. The ability of the tumor to...
  • 1.

    HundahlSAFlemingIDFremgenAMMenckHR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer1998;83:26382648.

    • Search Google Scholar
    • Export Citation
  • 2.

    KloosRTEngCEvansDB. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid2009;19:565612.

  • 3.

    GagelRFHoffAOCoteGJ. Medullary thyroid carcinoma. In: Braverman LE Utiger RD eds.Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text 9th ed.Philadelphia: Lippincott Williams & Wilkins; 2005:967988.

    • Search Google Scholar
    • Export Citation
  • 4.

    GagelRFCoteGJ. Pathogenesis of medullary thyroid carcinoma. In: Fagin JA ed.Thyroid Cancer. Boston/Dordrecht/London: Kluwer Academic; 1998:85103.

    • Search Google Scholar
    • Export Citation
  • 5.

    GertnerMEKebebewE. Multiple endocrine neoplasia type 2. Curr Treat Options Oncol2004;5:315325.

  • 6.

    RaueFFrank-RaueK. Multiple endocrine neoplasia type 2: 2007 update. Horm Res2007;68(Suppl 5):101104.

  • 7.

    SaadMFOrdonezNGRashidRK. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore)1984;63:319342.

    • Search Google Scholar
    • Export Citation
  • 8.

    MazzaferriEL. Thyroid carcinoma: Papillary and follicular. In: Mazzaferri EL Samaan NA eds.Endocrine Tumors. Cambridge: Blackwell Scientific Publications; 1993:278333.

    • Search Google Scholar
    • Export Citation
  • 9.

    HegedusL. Clinical practice. The thyroid nodule. N Engl J Med2004;351:17641771.

  • 10.

    CooperDSDohertyGMHaugenBR. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid2006;16:109142.

    • Search Google Scholar
    • Export Citation
  • 11.

    EzzatSSartiDACainDRBraunsteinGD. Thyroid incidentalomas. Prevalence by palpation and ultrasonography. Arch Intern Med1994;154:18381840.

    • Search Google Scholar
    • Export Citation
  • 12.

    RonELubinJHShoreRE. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res1995;141:259277.

    • Search Google Scholar
    • Export Citation
  • 13.

    SchneiderABBekermanCLelandJ. Thyroid nodules in the follow-up of irradiated individuals: comparison of thyroid ultrasound with scanning and palpation. J Clin Endocrinol Metab1997;82:40204027.

    • Search Google Scholar
    • Export Citation
  • 14.

    HornerMJRiesLAKrapchoM. SEER Cancer Statistics Review 1975–2006. Bethesda, MD: National Cancer Institute; 2009. Available at: http://seer.cancer.gov/csr/1975_2006/results_merged/sect_26_thyroid.pdf. Accessed March 15 2010.

    • Search Google Scholar
    • Export Citation
  • 15.

    JemalASiegelRWardE. Cancer statistics, 2009. CA Cancer J Clin2009;59:225249.

  • 16.

    MazzaferriELJhiangSM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med1994;97:418428.

    • Search Google Scholar
    • Export Citation
  • 17.

    LayfieldLJCibasESGharibHMandelSJ. Thyroid aspiration cytology: current status. CA Cancer J Clin2009;59:99110.

  • 18.

    FratesMCBensonCBCharboneauJW. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology2005;237:794800.

    • Search Google Scholar
    • Export Citation
  • 19.

    MazzaferriEL. Thyroid cancer in thyroid nodules: finding a needle in the haystack. Am J Med1992;93:359362.

  • 20.

    HammingJFGoslingsBMvan SteenisGJ. The value of fine-needle aspiration biopsy in patients with nodular thyroid disease divided into groups of suspicion of malignant neoplasms on clinical grounds. Arch Intern Med1990;150:113116.

    • Search Google Scholar
    • Export Citation
  • 21.

    ChanBKDesserTSMcDougallIR. Common and uncommon sonographic features of papillary thyroid carcinoma. J Ultrasound Med2003;22:10831090.

    • Search Google Scholar
    • Export Citation
  • 22.

    KoikeENoguchiSYamashitaH. Ultrasonographic characteristics of thyroid nodules: prediction of malignancy. Arch Surg2001;136:334337.

  • 23.

    HaymartMRRepplingerDJLeversonGE. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab2008;93:809814.

    • Search Google Scholar
    • Export Citation
  • 24.

    HenryJFDenizotAPucciniM. Early diagnosis of sporadic medullary cancers of the thyroid: value of systematic assay of calcitonin. Presse Med1996;25:15831588 [in French].

    • Search Google Scholar
    • Export Citation
  • 25.

    CooperDSDohertyGMHaugenBR. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid2009;19:11671214.

    • Search Google Scholar
    • Export Citation
  • 26.

    CheungKRomanSAWangTS. Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. J Clin Endocrinol Metab2008;93:21732180.

    • Search Google Scholar
    • Export Citation
  • 27.

    YehMWDemircanOItuartePClarkOH. False-negative fine-needle aspiration cytology results delay treatment and adversely affect outcome in patients with thyroid carcinoma. Thyroid2004;14:207215.

    • Search Google Scholar
    • Export Citation
  • 28.

    AsaSLBedardYC. Fine-needle aspiration cytology and histopathology. In: Clark OH Noguchi S eds.Thyroid Cancer: Diagnosis and Treatment. St Louis: Quality Medical Publishing; 2000:105126.

    • Search Google Scholar
    • Export Citation
  • 29.

    PaciniFFontanelliMFugazzolaL. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab1994;78:826829.

    • Search Google Scholar
    • Export Citation
  • 30.

    NiccoliPWion-BarbotNCaronP. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab1997;82:338341.

    • Search Google Scholar
    • Export Citation
  • 31.

    OzgenAGHamuluFBayraktarF. Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter. Thyroid1999;9:579582.

    • Search Google Scholar
    • Export Citation
  • 32.

    HorvitPKGagelRF. The goitrous patient with an elevated serum calcitonin—what to do?J Clin Endocrinol Metab1997;82:335337.

  • 33.

    HodakSPBurmanKD. The calcitonin conundrum—is it time for routine measurement of serum calcitonin in patients with thyroid nodules?J Clin Endocrinol Metab2004;89:511514.

    • Search Google Scholar
    • Export Citation
  • 34.

    PapiGCorselloSMCioniK. Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: a multicenter study. J Endocrinol Invest2006;29:427437.

    • Search Google Scholar
    • Export Citation
  • 35.

    KouvarakiMAShapiroSEPerrierND. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid2005;15:531544.

    • Search Google Scholar
    • Export Citation
  • 36.

    WohllkNCoteGJBugalhoMM. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab1996;81:37403745.

    • Search Google Scholar
    • Export Citation
  • 37.

    EliseiRRomeiCCosciB. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab2007;92:47254729.

    • Search Google Scholar
    • Export Citation
  • 38.

    GreeneFLPageDLFlemingIDeds.AJCC Cancer Staging Manual 6th ed.New York: Springer-Verlag; 2002.

  • 39.

    EdgeSBByrdDRComptonCCeds.AJCC Cancer Staging Manual 7th ed.New York: Springer; 2009.

  • 40.

    FlemingIDCooperJSHensonDEeds.AJCC Cancer Staging Manual 5th ed.Philadelphia: Lippincott Williams & Wilkins; 1997.

  • 41.

    DottoriniMEAssiASironiM. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer1996;77:15561565.

    • Search Google Scholar
    • Export Citation
  • 42.

    KebebewEItuartePHSipersteinAE. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer2000;88:11391148.

    • Search Google Scholar
    • Export Citation
  • 43.

    SamaanNASchultzPNHickeyRC. Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab1988;67:801805.

    • Search Google Scholar
    • Export Citation
  • 44.

    O'RiordainDSO'BrienTWeaverAL. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery1994;116:10171023.

    • Search Google Scholar
    • Export Citation
  • 45.

    LippmanSMMendelsohnGTrumpDL. The prognostic and biological significance of cellular heterogeneity in medullary thyroid carcinoma: a study of calcitonin, L-dopa decarboxylase, and histaminase. J Clin Endocrinol Metab1982;54:233240.

    • Search Google Scholar
    • Export Citation
  • 46.

    MendelsohnGWellsSAJrBaylinSB. Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease. Cancer1984;54:657662.

    • Search Google Scholar
    • Export Citation
  • 47.

    ByarDPGreenSBDorP. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer1979;15:10331041.

    • Search Google Scholar
    • Export Citation
  • 48.

    SzinnaiGMeierCKomminothPZumstegUW. Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis. Pediatrics2003;111:E132139.

    • Search Google Scholar
    • Export Citation
  • 49.

    RomeiCEliseiRPincheraA. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab1996;81:16191622.

    • Search Google Scholar
    • Export Citation
  • 50.

    EngCClaytonDSchuffeneckerI. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA1996;276:15751579.

    • Search Google Scholar
    • Export Citation
  • 51.

    MachensADralleH. Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg2007;31:957968.

  • 52.

    LearoydDLGosnellJElstonMS. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations. Clin Endocrinol (Oxf)2005;63:636641.

    • Search Google Scholar
    • Export Citation
  • 53.

    BrandiMLGagelRFAngeliA. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab2001;86:56585671.

  • 54.

    MachensANiccoli-SirePHoegelJ. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med2003;349:15171525.

  • 55.

    SkinnerMAMoleyJADilleyWG. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med2005;353:11051113.

  • 56.

    BurgeMRZeiseTMJohnsenMW. Risks of complication following thyroidectomy. J Gen Intern Med1998;13:2431.

  • 57.

    MiccoliPAntonelliASpinelliCL.Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident. Arch Surg1998;133:8993.

    • Search Google Scholar
    • Export Citation
  • 58.

    DralleHGimmOSimonD. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg1998;22:744750; discussion 750–741.

    • Search Google Scholar
    • Export Citation
  • 59.

    UdelsmanRLakatosELadensonP. Optimal surgery for papillary thyroid carcinoma. World J Surg1996;20:8893.

  • 60.

    PattouFCombemaleFFabreS. Hypocalcemia following thyroid surgery: incidence and prediction of outcome. World J Surg1998;22:718724.

  • 61.

    SosaJABowmanHMTielschJM. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg1998;228:320330.

    • Search Google Scholar
    • Export Citation
  • 62.

    BrierleyJTsangRSimpsonWJ. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid1996;6:305310.

    • Search Google Scholar
    • Export Citation
  • 63.

    BrierleyJMaxonHR. Radioiodine and external radiation therapy in the treatment of thyroid cancer. In: Fagin JA ed.Thyroid Cancer. Boston/Dordrecht/London: Kluwer Academic; 1998:285317.

    • Search Google Scholar
    • Export Citation
  • 64.

    van HeerdenJAGrantCSGharibH. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg1990;212:395400; discussion 400–391.

    • Search Google Scholar
    • Export Citation
  • 65.

    ScopsiLSampietroGBoracchiP. Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. A retrospective study of 109 consecutive patients. Cancer1996;78:21732183.

    • Search Google Scholar
    • Export Citation
  • 66.

    TisellLEHanssonGJanssonSSalanderH. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery1986;99:6066.

    • Search Google Scholar
    • Export Citation
  • 67.

    MoleyJFDebenedettiMKDilleyWG. Surgical management of patients with persistent or recurrent medullary thyroid cancer. J Intern Med1998;243:521526.

    • Search Google Scholar
    • Export Citation
  • 68.

    FlemingJBLeeJEBouvetM. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg1999;230:697707.

  • 69.

    KoberFHermannMHandlerAKrotlaG. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 14065.

    • Search Google Scholar
    • Export Citation
  • 70.

    KelleherFCMcDermottR. Response to sunitinib in medullary thyroid cancer. Ann Intern Med2008;148:567.

  • 71.

    ShermanSI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab2009;94:14931499.

    • Search Google Scholar
    • Export Citation
  • 72.

    SchlumbergerMChalletonCDe VathaireFParmentierC. Treatment of distant metastases of differentiated thyroid carcinoma. J Endocrinol Invest1995;18:170172.

    • Search Google Scholar
    • Export Citation
  • 73.

    NoceraMBaudinEPellegritiG. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer2000;83:715718.

    • Search Google Scholar
    • Export Citation
  • 74.

    SchlumbergerMJEliseiRBastholtL. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol2009;27:37943801.

    • Search Google Scholar
    • Export Citation
  • 75.

    WellsSAJrGosnellJEGagelRF. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol2010 ;28 :767772.

    • Search Google Scholar
    • Export Citation
  • 76.

    HongDYeLGagelR. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther2008;7:10011006.

    • Search Google Scholar
    • Export Citation
  • 77.

    BugalhoMJDominguesRBorgesA. A case of advanced medullary thyroid carcinoma successfully treated with sunitinib. Oncologist2009;14:10831087.

    • Search Google Scholar
    • Export Citation
  • 78.

    GoulartBCarrLMartinsRG. Phase II study of sunitinib in iodine refractory, well-differentiated thyroid cancer (WDTC) and metastatic medullary thyroid carcinoma (MTC) [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 6062.

    • Search Google Scholar
    • Export Citation
  • 79.

    SpectorEFranklinMJTruskinovskyAMDudekAZ. Sorafenib induces partial response in metastatic medullary thyroid carcinoma. Acta Oncol2010;49:104106.

    • Search Google Scholar
    • Export Citation
  • 80.

    SalgiaRShermanSHongDS. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC) [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 3522.

    • Search Google Scholar
    • Export Citation
  • 81.

    SugawaraMGeffnerDLMartinezDHershmanJM. Novel treatment of medullary thyroid cancer. Curr Opin Endocrinol Diabetes Obes2009;16:367372.

    • Search Google Scholar
    • Export Citation
  • 82.

    SantarpiaLYeLGagelRF. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma. J Intern Med2009;266:99113.

    • Search Google Scholar
    • Export Citation
  • 83.

    CakirMGrossmanAB. Medullary thyroid cancer: molecular biology and novel molecular therapies. Neuroendocrinology2009;90:323348.

  • 84.

    CerratoADe FalcoVSantoroM. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. J Mol Endocrinol2009;43:143155.

    • Search Google Scholar
    • Export Citation
  • 85.

    ChatalJFCampionLKraeber-BodereF. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol2006;24:17051711.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 331 331 21
PDF Downloads 32 32 3
EPUB Downloads 0 0 0